NEO: Gunggunge utang jangka dawa NeoGenomics Laboratories

NeoGenomics, Inc. (NEO) specializes in oncology diagnostics, where lengthy medical protocol cycles ensure a steady stream of orders and high margins. The price action of the securities clearly demonstrates the asset's dynamics, while the long-term liabilities figure stands at 0.44. The business's financial stability relies on the volume of tests performed, US insurance payouts, and investments by pharmaceutical behemoths into scientific research.

Investors use this indicator to assess the issuer's creditworthiness and the risk of long-term capital insolvency. The metric aggregates all liabilities with a maturity of more than one year; therefore, the size of the company's long-term debt allows for an assessment of the financial stability of NeoGenomics, Inc. (NEO) when implementing costly partnerships with oncology clinics and pharmaceutical behemoths in the field of genetic testing.